CA2563365A1 — Multiple unit dose drug delivery system
Assigned to Mystic Pharmaceuticals Inc · Expires 2005-11-03 · 21y expired
What this patent protects
The present disclosure is directed to devices that administer single or multiple doses of one or more substances to the eye, nose, or ear of a user. The precise and repeatable dosing features of the presently disclosed devices overcome many of the disadvantages associated with kn…
USPTO Abstract
The present disclosure is directed to devices that administer single or multiple doses of one or more substances to the eye, nose, or ear of a user. The precise and repeatable dosing features of the presently disclosed devices overcome many of the disadvantages associated with known methods for dispensing substances to, for example, the eye of a user. The devices administer precise doses of a substance to a precise location from ampoules that may be single-dose or two-dose ampoules, which may be externally or internally pierced.
Drugs covered by this patent
- Tobi (tobramycin) · Novartis
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.